Approval allows use of therascreen® EGFR RGQ PCR Kit as a companion diagnostic for Pfizer’s VIZIMPRO® (dacomitinib) in patients with non-small cell lung cancer Germantown, Maryland, and Hilden, Germany, September 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA Supplement... Read more
Hilden, Germany, and Germantown, Maryland, September 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United Nations meeting on tuberculosis (TB) to mobilize $13 billion a year by 2022 to implement prevention and care for TB, the world’s most deadly infectious disease.... Read more
DNAnexus selected by BHCGC to serve as its primary portal for communication and data sharing with the All of Us Research Program. September 27, 2018 08:00 AM Eastern Daylight Time MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–The Baylor College of Medicine Human Genome Sequencing Center (HGSC) today announced participation in the National Institutes of Health All of Us Research Program, a large-scale effort to advance... Read more
Download as PDF SEPTEMBER 27, 2018 MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ — Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible... Read more
Next Generation Sequencing (NGS) Kit to Improve Speed and Accuracy of M. Tuberculosis (MTB) Drug Sensitivity Testing (DST) at a Fraction of the Current Cost of Sequencing BETHESDA, Maryland, Sept. 25, 2018 /PRNewswire/ — Longhorn Vaccines and Diagnostics LLC (LHNVD), a private pre-analytical systems and molecular solutions company, is pleased to announce the validation of its newest technology,... Read more
IsoPlexis’ groundbreaking platform has been shown in key studies to predict patient response to cell therapy The IsoLight® platform: • profiles responses at the single cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex patient response to cancer immunotherapies • advances high-need areas of cell therapy research,... Read more
Basel, 18 September 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event: Key data for Roche’s lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer Agenda Roche lung cancer portfolio key data IMpower133: Primary PFS, OS, and Safety in a Ph1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in... Read more
Basel, 18 September 2018 Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases Roche launches an app ecosystem with the first two clinical decision support apps The apps query globally-renowned resources based on real-world data Patient-specific results lead to more personalised treatment decisions by oncology care teams Roche (SIX:... Read more
Hilden, Germany, and Saluggia, Italy, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) today announced the introduction of an automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test on widely used immunodiagnostic instruments from... Read more
Hilden, Germany, and Ann Arbor, Michigan, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced a strategic partnership to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing. These next-generation systems are specifically designed to help clinical molecular diagnostic laboratories process... Read more